MREO Stock Forecast & Price Target

Mereo BioPharma Group is a promising investment opportunity due to its pipeline of late-stage clinical programs targeting rare diseases, with setrusumab and alvelestat showing promising clinical results in osteogenesis imperfecta and alpha-1 antitrypsin deficiency-associated lung disease, respectively. Despite initial setbacks in its Orbit and Cosmic trials, Mereo is in ongoing discussions with the FDA to understand what additional data is needed for a potential BLA submission for setrusumab. With a strong safety profile and improved disease severity and pain/symptoms in pediatric and teen patients, setrusumab has the potential to address a significant unmet need in the OI market. Alvelestat has also shown promising results, with a reduction in annualized exacerbation rate by 36% and a 48% reduction in moderate/severe exacerbations, and has a low safety risk. Overall, Mereo's established presence in the drug development industry and its potential to capture a share of the complex and price-sensitive rare disease market make it a worthwhile investment opportunity.

Mereo BioPharma Group is facing potential challenges with its late-stage clinical product candidates, as regulatory discussions for setrusumab, as well as the appreciation for Europe rights to Vantictumab, remain uncertain. Additionally, the lack of current product sales and significant financial milestones could impact the company's financial viability in the near term.